Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Within AML, CD123 expression was lower in erythroid/megakaryocytic leukemia, higher in NPM1 mutated and FLT3-ITD mutated leukemia, and comparable between LSC and leukemic blasts.
|
30450744 |
2019 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Also, the <i>ex vivo</i> and <i>in vivo</i> models were used to test the synergistic effects of melatonin and sorafenib against leukemia with FLT3/ITD mutation.
|
31281512 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia.
|
31688198 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When compared with Western blotting results, FLT3 protein expression levels in leukemia patient's bone marrow samples were demonstrated in the same trend.
|
30737839 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotreatment with FLT3 inhibitors and inhibitors of JAK or PIM kinases blocks GM-CSF and IL-3 rescue of cell survival in vitro and in vivo.
|
30944098 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flt3 is an oncogenic kinase involved in different types of leukemia.
|
30703688 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of FMS-like tyrosine kinase 3 protein with internal tandem duplication (FLT3-ITD) mutation protein was related to the poor prognosis and disease progression of leukemia.
|
30572745 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the results of the present study showed that the overexpression of FLT3 is a potential risk factor in leukemia.
|
29257272 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The specific cytotoxicity against FLT3<sup>+</sup> leukemia cell lines, primary AML cells, and normal hematopoietic progenitor stem cells (HPSCs) in vitro were evaluated.
|
29716633 |
2018 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By doing so, STAT5 activation promotes an overall elevation of ROS level, which acts as a feed-forward loop, especially in high risk Fms-related tyrosine kinase 3 (FLT3) mutant leukemia.
|
30262727 |
2018 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prevalence of oncogenic FLT3 and the dependency on its constitutively activated kinase activity for leukemia growth make this protein an attractive target for therapeutic intervention.
|
29343975 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggest that ATO is a potential candidate to study in clinical trials in combination with FLT3 TKIs to improve the treatment of FLT3/ITD+ leukemia.
|
30250637 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, combined treatment of <i>FLT3</i><sup>D835H</sup> PDX-ALL with the ATP-competitive group I PAK inhibitor FRAX486 and midostaurin in vivo significantly prolonged leukemia progression-free survival compared with midostaurin monotherapy or control.
|
30301811 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the combination of FLT3i and PARP1i eliminated FLT3(ITD)-positive quiescent and proliferating leukemia stem cells, as well as leukemic progenitors, from human and mouse leukemia samples.
|
29784639 |
2018 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aberrant expression and function of FLT3 are strongly related to leukemia, especially acute myeloid leukemia.
|
28748750 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting of USP10 showed efficacy in preclinical models of mutant-FLT3 AML, including cell lines, primary patient specimens and mouse models of oncogenic-FLT3-driven leukemia.
|
28967922 |
2017 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To define the role of Flt3 in AML with high Hoxa9/Meis1, we treated mice with Hoxa9/Meis1-induced AML with the Flt3 inhibitor AC220, used an Flt3-ligand (FL-/-) knockout model, and investigated whether overexpression of Flt3 could induce leukemia together with overexpression of Hoxa9.
|
27617578 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic characterization of NA9-induced phenotypes suggested interference with PVR (Flt1-4 RTK homolog) signaling, which is similar to functional interactions observed in mammals between Flt3 and HOXA9 in leukemia.
|
27838340 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we review current findings on the role of mutated FLT3 in leukemia and the development of FLT3 inhibitors for therapeutic use to treat AML.
|
28538663 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1 cooperates with FLT3-ITD to induce leukemia.
|
28213513 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results reveal a novel mode of FLT3 regulation essential for leukemia growth, which may aid in designing a targeted therapy to treat human myeloid leukemia.
|
28107692 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
It worked synergistically with FLT3 inhibitors to suppress leukemia growth in vitro and in xenograft mouse models.
|
27708062 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
|
27103744 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, K562, OCI-AML3 and THP-1 (leukemia cell lines lacking FLT3-ITD) were resistant to cabozantinib, showing IC50 values in the micromolar range.
|
27060207 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was also confirmed that FL impaired the anti-leukemia effects of FLT3 inhibitors on primary AML cells.
|
27331411 |
2016 |